Image-Guided Monitoring of Mitochondria and Blood–Brain Barrier Dysfunction in Amyotrophic Lateral Sclerosis Mice
Open Access
- 1 January 2025
- journal article
- Published by American Association for the Advancement of Science (AAAS) in Biomaterials Research
- Vol. 29, 0162
Abstract
Early detection of amyotrophic lateral sclerosis (ALS) progression is critical for improving disease management and therapeutic outcomes. However, the clinical heterogeneity and variability in ALS symptoms often lead to delayed diagnosis and suboptimal therapeutic interventions. Since mitochondrial dysfunction is a hallmark of ALS, we hypothesized that monitoring mitochondrial function could serve as a reliable strategy for early diagnosis and therapeutic monitoring of ALS. To address this, we synthesized and characterized 2 novel near-infrared fluorophores, ALS04 and ALS05, designed to target mitochondria and lysosomes. Their physicochemical properties, serum protein binding, fluorescence characteristics, photostability, and pharmacokinetics were systematically evaluated. We found that benzothiazole-based fluorophores exhibit excellent mitochondrial targeting, optimal optical properties, biocompatibility, and favorable biodistribution in vivo. Interestingly, ALS04 showed superior mitochondrial accumulation compared to ALS05, despite their similar physicochemical properties. This enhanced accumulation can be attributed to the lower molecular weight and higher lipophilicity of ALS04. Real-time fluorescence imaging revealed a substantial reduction in ALS04 signals in mitochondrial-rich tissues such as brown fat, highlighting its potential for monitoring mitochondrial dysfunction in early-stage ALS. Furthermore, the detection of ALS04 in the mouse brain suggests its ability to monitor blood–brain barrier hyperpermeability, another key feature of ALS pathology. These findings establish ALS04 as a promising noninvasive imaging tool for monitoring biomarkers associated with ALS progression. Its ability to detect early-stage pathophysiological changes in an ALS mouse model highlights its potential for advancing our understanding of ALS mechanisms and facilitating the identification of novel therapeutic targets.Keywords
Funding Information
- National Cancer Institute (R01CA280968)
- National Heart, Lung, and Blood Institute (R01HL163273)
- Ministry of Health and Welfare (HI22C2063)
This publication has 34 references indexed in Scilit:
- Multispectral image-guided surgery in patientsNature Biomedical Engineering, 2020
- The Blood–Brain Barrier (BBB) ScoreJournal of Medicinal Chemistry, 2019
- Novel behavioural characteristics of the superoxide dismutase 1 G93A (SOD1G93A) mouse model of amyotrophic lateral sclerosis include sex‐dependent phenotypesGenes, Brain and Behavior, 2019
- Mitochondria-Targeted Triphenylphosphonium-Based Compounds: Syntheses, Mechanisms of Action, and Therapeutic and Diagnostic ApplicationsChemical Reviews, 2017
- Effects of target binding kinetics onin vivodrug efficacy: koff, konand rebindingBritish Journal of Pharmacology, 2016
- Comparative study of behavioural tests in the SOD1G93A mouse model of amyotrophic lateral sclerosisExperimental Animals, 2015
- Simultaneous Mapping of Pan and Sentinel Lymph Nodes for Real-Time Image-Guided SurgeryTheranostics, 2014
- Synthesis and In Vivo Fate of Zwitterionic Near‐Infrared FluorophoresAngewandte Chemie International Edition, 2011
- Near IR Heptamethine Cyanine Dye–Mediated Cancer ImagingClinical Cancer Research, 2010
- Ultrastructure of blood–brain barrier and blood–spinal cord barrier in SOD1 mice modeling ALSBrain Research, 2007